4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

3 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

3 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4/A - Mural Oncology plc (0001971543) (Issuer)

Rodman & Renshaw initiated coverage of Mural Oncology with a rating of Buy and set a new price target of $15.00

Morgan Stanley initiated coverage of Mural Oncology with a rating of Overweight and set a new price target of $13.00

4 - Mural Oncology plc (0001971543) (Issuer)

EFFECT - Mural Oncology plc (0001971543) (Filer)

SCHEDULE 13G - Mural Oncology plc (0001971543) (Subject)

SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

S-3 - Mural Oncology plc (0001971543) (Filer)

10-Q - Mural Oncology plc (0001971543) (Filer)

8-K - Mural Oncology plc (0001971543) (Filer)

144 - Mural Oncology plc (0001971543) (Subject)

144 - Mural Oncology plc (0001971543) (Subject)

8-K - Mural Oncology plc (0001971543) (Filer)

8-K - Mural Oncology plc (0001971543) (Filer)

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. "George has been a leader in business development for 30 years. There has been a great deal of industry interest in cytokine programs as of late, and Mural is in the fortunate position of having two potentially registrational studies reading out in the first half of 2025, as well as two preclinical programs hea

Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced solid tumors, including in platinum-resistant ovarian cancer (PROC), which does not typically respond to immunotherapies Safety profile and anti-tumor activity observed in ARTISTRY-1 supported the company's two potentially registrational trials, with readouts expected in late Q1/early Q2 2025 for PROC and Q2 2025 for mucosal melanoma WALTHAM, Mass. and DUBLIN, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developi

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences. Jefferies London Healthcare Conference 1x1 meetings with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, Adam Cutler, Chief Financial Officer Date: Tuesday, November 19-Wednesday, November 20, 2024 Piper Sandler 36th Annual Healthcare Conference Fireside chat with Caroline Loew, Ph.D.

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural's IL-18 variants, reinforcing pursuit of IND-enabling studies with candidate nomination anticipated by the end of 2024, and IND submission expected in Q4 2025 Additional preclinical data from Mural's IL-12 program suggest the company's approach may unlock the potential of IL-12 as a therapeutic by mitigating the cytokine's historic toxicity; company continues to expect candidate nomination by

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on November 1, the Company granted to five newly hired employees (i) non-statutory stock options to purchase an aggregate of 23,500 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 12,500 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees enter

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced three upcoming poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 6-10, 2024 in Houston. The company will present tumor microenvironment pharmacodynamic data from the phase 1/2 ARTISTRY-3 study, an evaluation of less frequent dosing of nemvaleukin, Mural's engineered interleukin-2 (IL-2). Additionally, Mural will share data from it

WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on October 1, the Company granted to three newly hired employees (i) non-statutory stock options to purchase an aggregate of 28,525 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 14,975 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees ente

Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new cytokine-based immunotherapies Mural remains on track to deliver key data readouts in potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025 WALTHAM, Mass. and DUBLIN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, t

Rodman & Renshaw analyst Tony Butler initiates coverage on Mural Oncology (NASDAQ:MURA) with a Buy rating and announces Price Target of $15.

Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested, the company said.

For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects in preclinical modelsData presented suggest dual-targeted, subunit approach to engineered IL-12 may mitigate cytokine's hallmark toxicity without compromising efficacy

Morgan Stanley analyst Judah Frommer initiates coverage on Mural Oncology (NASDAQ:MURA) with a Overweight rating and announces Price Target of $13.

Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(3.57) per share. This is a 22.68 percent decrease over losses of $(2.91) per share from the same period last year.

Shares of Applied UV, Inc. (NASDAQ:AUVI) shares jumped in pre-market trading after the company reported third-quarter results. Applied UV posted a quarterly loss of 32 cents per share, versus a year-ago loss of $1.20 per share. The company’s quarterly sales came in at $11.45 million up from $5.88 million, according to data from Benzinga Pro. Applied UV reaffirmed its previous guidance of approximately $45 million in revenue for 2023. Applied UV shares rose 96.1% to $0.29 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Bruush Oral Care Inc. (NASDAQ:BRSH) shares rose 172.2% to $0.4601 in pre-market trading. Brüush received Nasdaq notification reg

Shares of Dolby Laboratories, Inc. (NYSE:DLB) fell during Friday’s session following weak guidance. Dolby Laboratories reported quarterly earnings of 65 cents per share, surpassing the analyst consensus estimate of 53 cents. The company reported quarterly sales of $290.56 million, which topped the analyst consensus estimate of $290.20 million, according to data from Benzinga Pro. Dolby Laboratories said it sees first-quarter earnings between 80 cents and 95 cents per share, versus the $1.08 estimate. The company sees total revenue in a range between $300 million and $330 million, versus the estimate of $353.67 million. Dolby Laboratories shares dropped 8.3% to $80.49 Here are some other